Idelalisib - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for idelalisib and what is the scope of patent protection?

Idelalisib is the generic ingredient in one branded drug marketed by Gilead Sciences Inc and is included in one NDA. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Idelalisib has one hundred and sixty patent family members in forty-six countries.

There are two drug master file entries for idelalisib. One supplier is listed for this compound.

Summary for idelalisib

International Patents:	160
US Patents:	12
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	2
Suppliers / Packagers:	1
Bulk Api Vendors:	80
Clinical Trials:	56
Patent Applications:	221
Formulation / Manufacturing:	see details
DailyMed Link:	idelalisib at DailyMed

Recent Clinical Trials for idelalisib

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Fondazione Italiana Linfomi ONLUS	Phase 2
Oregon Health and Science University	Phase 1
Prospect Creek Foundation	Phase 1

See all idelalisib clinical trials

Pharmacology for idelalisib

Drug Class	Kinase Inhibitor
Mechanism of Action	Kinase Inhibitors Cytochrome P450 3A Inhibitors

Synonyms for idelalisib

(S)-2-(1-((9H-Purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
(S)-2-(1-(1H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
(S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
(S)-5-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one
1146702-54-6
1453810-72-4
40L
5-fluoro-3-phenyl-2-((1s)-1-(9h-purin-6-ylamino)propyl)-4(3h)-quinazolinone
5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one
5-fluoro-3-phenyl-2-[(1S)-1-(3H-purin-6-ylamino)propyl]quinazolin-4(3H)-one
5-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]quinazolin-4-one
5-Fluoro-3-Phenyl-2-[(1s)-1-(7h-Purin-6-Ylamino)propyl]quinazolin-4(3h)-One
5-FLUORO-3-PHENYL-2-[(1S)-1-(9H-PURIN-6-YLAMINO)PROPYL]-4(3H)-QUINAZOLINONE
5-fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]quinazolin-4-one
870281-82-6
ABP000109
AC-28394
AJ-64558
AK145603
AKOS022186334
AOB87313
AX8224801
BC638838
BCP02532
BCP9000471
BCPP000307
BDBM50403068
BRD-K60866521-001-01-4
C22H18FN7O
CAL 101
CAL-101
CAL-101 (GS-1101)
CAL-101 (Idelalisib, GS-1101)
CAL-101/CAL101
CAL101
CAL101;S2226;870281-82-6
cc-41
CHEBI:82701
CHEMBL2216870
CS-0256
D10560
DB09054
EX-A1242
EX-A330
FT-0699107
FT-0773473
GS 1101
GS-1101
GS-11CAL-101
GTPL6741
HY-13026
Idelalisib (CAL-101 GS-1101)
Idelalisib (JAN/USAN/INN)
Idelalisib [USAN:INN]
Idelalisib; CAL-101
IFSDAJWBUCMOAH-HNNXBMFYSA-N
J-517532
KB-48629
KS-000007GA
LS41100
MLS006010985
MolPort-016-633-355
NCGC00262603-01
NCGC00262603-02
PB25727
Q-4533
QCR-36
RL05396
s2226
SC-86075
SCHEMBL16782604
SCHEMBL356400
SMR004702787
ST2408278
SW219823-1
Tube701
UNII-YG57I8T5M0
X7435
YG57I8T5M0
ZINC13986658
Zydelig
Zydelig (TN)

US Patents and Regulatory Information for idelalisib

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	ZYDELIG	idelalisib	TABLET;ORAL	205858-002	Jul 23, 2014		RX	Yes	Yes	Start Trial	Start Trial	Y	Y		Start Trial
Gilead Sciences Inc	ZYDELIG	idelalisib	TABLET;ORAL	205858-002	Jul 23, 2014		RX	Yes	Yes	Start Trial	Start Trial		Y		Start Trial
Gilead Sciences Inc	ZYDELIG	idelalisib	TABLET;ORAL	205858-002	Jul 23, 2014		RX	Yes	Yes	Start Trial	Start Trial		Y		Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for idelalisib

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Cyprus	1117672	Start Trial
Ukraine	76103	Start Trial
Denmark	1438052	Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for idelalisib

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1761540	300867	Netherlands	Start Trial	PRODUCT NAME: IDELALISIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/14/938 20140919
1761540	269 7-2017	Slovakia	Start Trial	PRODUCT NAME: IDELALISIB VO VSETKYCH FORMACH CHRANENYCH ZA- KLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/14/938 20140919
1761540	122017000008	Germany	Start Trial	PRODUCT NAME: LDELALISIB ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/938 20140918
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.